Proterris

Proterris, Inc. is a clinical-development stage company based in Boston, Massachusetts, specializing in the therapeutic applications of low-dose carbon monoxide (CO). Founded in 2012, Proterris is focused on developing inhaled CO and CO-releasing molecules for various medical conditions, including delayed graft function in renal transplant recipients and acute liver failure. The company also explores treatment opportunities for non-alcoholic steatohepatitis (NASH), acute kidney injury, renal fibrosis, and idiopathic pulmonary fibrosis, among other indications. By leveraging a strong intellectual property position, Proterris aims to address a range of fibrotic and ischemia-reperfusion injury disorders, providing innovative solutions in the field of therapeutic carbon monoxide applications.